Researchers have discovered a previously unknown cardiac molecule that could provide a key to treating, and preventing, heart failure.
The newly discovered molecule provides the heart with a tool to block a protein that orchestrates genetic disruptions when the heart is subjected to stress, such as high blood pressure.
Researchers led by a team at Indiana University School of Medicine have discovered a cardiac compound that could lead to new treatment for heart failure.
Credit: Indiana University
When the research team, led by Ching-Pin Chang, M.D., Ph.D., associate professor of medicine at the Indiana University School of Medicine, restored levels of the newly discovered molecule in mice experiencing heart failure, the progression to heart failure was stopped. The research was published in the online edition of the journal Nature.
The newly discovered molecule is known as a long non-coding RNA. RNA's usual role is to carry instructions -- the code -- from the DNA in a cell's nucleus to the machinery in the cell that produces proteins necessary for cell activities. In recent years, scientists have discovered several types of RNA that are not involved in protein coding but act on their own. The role in the heart of long non-coding RNA has been unknown.
But the researchers determined that the newly discovered non-coding RNA, which they named Myheart -- for myosin heavy-chain-associated RNA transcript -- is responsible for controlling a protein called BRG1 (pronounced "berg-1"). In earlier research published in Nature in 2010, Dr. Chang and his colleagues discovered that BRG1 plays a crucial role in the development of the heart in the fetus.
But as the heart grows and needs to mature into its adult form, BRG1 is no longer needed, so very little of it is produced. That is, until the adult heart is subjected to significant stress such as high blood pressure or damage from a heart attack.
Dr. Chang's previous research showed that in those conditions, BRG1 re-emerges and begins altering the heart's genetic activity, leading to heart failure. At the same time, production of Myheart is suppressed, so BRG1 can latch onto the DNA and alter the genetic material unchecked.
In the current Nature paper, the researchers reported that in mice with stress-induced high levels of BRG1, they were able to restore Myheart to normal levels using gene transfer technology. Restoring Myheart levels blocked BRG1 actions and prevented heart failure, they said.
"I think of Myheart as a molecular crowbar that pries BRG1 off the genomic DNA and prevents it from manipulating genetic activity," said Dr. Chang, director of molecular and translational medicine at the Krannert Institute of Cardiology.
Although the results in mice would suggest testing Myheart against heart failure in humans, it is too large -- by molecular standards -- to be delivered as a drug, Dr. Chang said.
So he and his colleagues now are working to identify smaller portions of the Myheart molecule that are key to its ability to block BRG1. Such a subsection of the Myheart molecule could lead to a compound to test in human trials.
In addition to Dr. Chang and Pei Han, Ph.D., first author of the paper, investigators contributing to the research included Wei Li, Jin Yang and Peng-Sheng Chen of the IU School of Medicine; Chiou-Hong Lin, Ching Shang, Sylvia T. Nuernberg, Kevin Kai Jin, Weihong Xu, Chieh-Yu Lin, Chien-Jung Lin, Yiqin Xiong, Huan-Chieh Chien, Euan Ashley, Daniel Bernstein and Thomas Quertermous of the Stanford University School of Medicine; Bin Zhou of the Albert Einstein College of Medicine; and Huei-Sheng Vincent Chen of the Sanford/Burnham Medical Research Institute.
The research was supported by the American Heart Association (AHA; Established Investigator Award 12EIA8960018); the National Institutes of Health (NIH; HL118087, HL121197, HL109512, HL105194, HL78931, HL71140, HL116997, HL111770); California Institute of Regenerative Medicine (CIRM; RN2-00909, RB2-01512, RB4-06276); Stanford Heart Center Research Program; the IU School of Medicine-IU Health Strategic Research Initiative; the IU Physician-Scientist Initiative, endowed by Lilly Endowment; the Lucile Packard Foundation for Children's Health; the March of Dimes Foundation (#6-FY11-260); the Oak Foundation; and the Baxter Foundation.
Eric Schoch | Eurek Alert!
Inflammation Triggers Unsustainable Immune Response to Chronic Viral Infection
24.10.2016 | Universität Basel
Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg
Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion
Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
24.10.2016 | Earth Sciences
24.10.2016 | Life Sciences
24.10.2016 | Physics and Astronomy